HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00417482

Stopping antipsychotic treatment after improvement in Alzheimer-related agitation or psychosis

About this titleRead the official source — NCT00417482
Medication studyAges 50–95United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 50 years to 95 years.

Listed locations
Tuscaloosa and 6 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2004
Recruitment status
Completed
Enrollment listed in the registry
180
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 50 Years to 95 Years
Official registry ID
NCT00417482
Official title
Show the full official title

Antipsychotic Discontinuation in Alzheimer's Disease

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tuscaloosa · Los Angeles · Norwalk

3 more locations
  • Iowa City
  • New York
  • North Charleston
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Did this study involve medication?

Yes. The study involved medication, including risperidone.

Who was this study for?

Listed age limits: 50 years to 95 years.

Want to explore more studies?

Explore studies